» Articles » PMID: 25654105

The Effect of Primary Cancer Cell Culture Models on the Results of Drug Chemosensitivity Assays: the Application of Perfusion Microbioreactor System As Cell Culture Vessel

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2015 Feb 6
PMID 25654105
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

To precisely and faithfully perform cell-based drug chemosensitivity assays, a well-defined and biologically relevant culture condition is required. For the former, a perfusion microbioreactor system capable of providing a stable culture condition was adopted. For the latter, however, little is known about the impact of culture models on the physiology and chemosensitivity assay results of primary oral cavity cancer cells. To address the issues, experiments were performed. Results showed that minor environmental pH change could significantly affect the metabolic activity of cells, demonstrating the importance of stable culture condition for such assays. Moreover, the culture models could also significantly influence the metabolic activity and proliferation of cells. Furthermore, the choice of culture models might lead to different outcomes of chemosensitivity assays. Compared with the similar test based on tumor-level assays, the spheroid model could overestimate the drug resistance of cells to cisplatin, whereas the 2D and 3D culture models might overestimate the chemosensitivity of cells to such anticancer drug. In this study, the 3D culture models with same cell density as that in tumor samples showed comparable chemosensitivity assay results as the tumor-level assays. Overall, this study has provided some fundamental information for establishing a precise and faithful drug chemosensitivity assay.

Citing Articles

Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer.

Yousafzai N, El Khalki L, Wang W, Szpendyk J, Sossey-Alaoui K Cancers (Basel). 2024; 16(5).

PMID: 38473244 PMC: 10931050. DOI: 10.3390/cancers16050883.


Screening Evaluation of Antiproliferative, Antimicrobial and Antioxidant Activity of Lichen Extracts and Secondary Metabolites In Vitro.

Kello M, Goga M, Kotorova K, Sebova D, Frenak R, Tkacikova L Plants (Basel). 2023; 12(3).

PMID: 36771693 PMC: 9919983. DOI: 10.3390/plants12030611.


Biomimetic Hydrogels in the Study of Cancer Mechanobiology: Overview, Biomedical Applications, and Future Perspectives.

Sahan A, Baday M, Patel C Gels. 2022; 8(8).

PMID: 36005097 PMC: 9407355. DOI: 10.3390/gels8080496.


Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs.

Brumskill S, Barrera L, Calcraft P, Phillips C, Costello E J Physiol Biochem. 2021; 79(1):223-234.

PMID: 34865180 PMC: 9905179. DOI: 10.1007/s13105-021-00857-2.


Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time.

Bilbao M, Katz C, Kass S, Smith D, Hunter K, Warshal D Biomolecules. 2021; 11(11).

PMID: 34827710 PMC: 8615646. DOI: 10.3390/biom11111711.


References
1.
Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H . Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy. 2001; 47(2):136-42. DOI: 10.1159/000048513. View

2.
Oktem G, Sercan O, Guven U, Uslu R, Uysal A, Goksel G . Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids. Oncol Rep. 2014; 32(2):641-9. DOI: 10.3892/or.2014.3252. View

3.
Abbott A . Cell culture: biology's new dimension. Nature. 2003; 424(6951):870-2. DOI: 10.1038/424870a. View

4.
Barry M, Behnke C, Eastman A . Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990; 40(10):2353-62. DOI: 10.1016/0006-2952(90)90733-2. View

5.
Bown N, Reid M, Malcolm A, Davison E, Craft A, Pearson A . Cytogenetic abnormalities of small round cell tumours. Med Pediatr Oncol. 1994; 23(2):124-9. DOI: 10.1002/mpo.2950230210. View